Clinical trials: Papilloma Virus, Human
Cervical Cancer
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
- Trial name
- NCT04646005
- Testing
- Cemiplimab, ISA101b
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 113 people
- Sponsor
- Regeneron Pharmaceuticals
Human Papillomavirus Infection, Anal HPV Infection
Epidemiology of Anal Human Papillomavirus Carriage in Female Solid Organ Transplant Recipients With More Than 10 Years of Immunosuppression
Anal canal cancer is primarily associated with persistent infection by high-risk human papillomavirus (HR-HPV), particularly HPV-16.
- Conditions
- Human Papillomavirus Infection, Anal HPV Infection, Human Papillomavirus 16 Infection
- Trial name
- EPAHTOS (NCT07858201)
- Testing
- Anal Self-Sampling for High-Risk HPV Detection
- Volunteers
- 190 people
- Sponsor
- University Hospital, Montpellier
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Uterine Cervical Cancer
Community Awareness, Resources and Education (CARE II): Project 3
Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix.
- Trial name
- NCT01299714
- Where
- 4 sites in United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Human Papillomavirus Infection, Human Papillomavirus Infections
Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With Human Papillomavirus (HPV)
This randomized, open-label, multicenter clinical study is designed to evaluate Papilozumib® vaginal gel in women aged 30 to 50 years who test positive for human papillomavirus (HPV) and present with either normal cervical…
- Trial name
- NCT07762209
- Testing
- Papilozumib vaginal gel, Papilozumib oral supplement
- Where
- 6 sites in Spain
- Volunteers
- 81 people
- Sponsor
- Hifas da Terra S.L.
Oropharyngeal Squamous Cell Carcinoma Recurrent
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda®) in people with human papillomavirus subtype 16 positive (HPV16+) head and neck cancer starting in the middle part of the…
- Trial name
- NCT06513884
- Testing
- HB-202/HB-201 alternating 2-vector therapy, Pembrolizumab
- Sponsor
- Hookipa Biotech GmbH
Human Papilloma Virus
Zinc Sulfate for Human Papillomavirus (HPV)
The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time…
- Trial name
- NCT03404310
- Testing
- Zinc Sulfate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Corewell Health West
Papillomavirus Infections
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
The primary objective of this study is the estimation of the human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58 seroconversion at 1 month post last dose (Month 7) following 3 doses and 2 doses of the 9-valent human…
- Trial name
- NCT04772534
- Testing
- 9vHPV vaccine
- Where
- 12 sites in Japan
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Human Papilloma Virus
The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV
The study will evaluate 300 people living with HIV that attend the Vivent Clinic for HIV care. We will characterize our population and include age, race/ethnicity, sex at birth, tobacco use, alcohol use, other comorbidities, HPV…
- Trial name
- SWISH (NCT06205511)
- Testing
- Oral HPV Sample
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Vivent Health
Human Papillomavirus (HPV) Vaccine
Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule
The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as well as evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of medically significant conditions…
- Trial name
- HPV-022 PRI (NCT00572000)
- Testing
- HPV-16/18 L1 VLP AS04 vaccine
- Where
- Vietnam
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- National Institute for Control of Vaccine and Biologicals
Cervical Intraepithelial Neoplasia, Papillomavirus Infection
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all…
- Trial name
- NCT00316706
- Testing
- GSK Biologicals' HPV-16/18 Vaccine (Cervarix™), Havrix™
- Where
- 28 sites in Colombia, Germany and 3 more
- Volunteers
- 1,245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
Oral Rigosertib for Squamous Cell Carcinoma
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01807546
- Testing
- rigosertib
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Traws Pharma, Inc.
Cervical Cancer
Home-based Cervical Cancer Screening Project
Cervical cancer is a public health problem in Cameroon.In 2020, the country had a crude incidence of 20.2 per 100 000 women for an incidence to mortality ratio of 0.65.
- Trial name
- CASAHO (NCT06166420)
- Testing
- Experimental, Active comparator
- Where
- Cameroon
- Volunteers
- 2,079 people, healthy volunteers welcome
- Sponsor
- Prof. Patrick Petignat
Transgenderism, Cervical Cancer
Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men
Transgender men are individuals born genetically female that have a gender identity that is incongruent with their biological sex.
- Conditions
- Transgenderism, Cervical Cancer, Human Papilloma Virus
- Trial name
- NCT04154358
- Testing
- HPV testing
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Augusta University
Human Papillomavirus
A Phase I Clinical Trial of an HPV Therapeutic Vaccine
This study will consist of 300 women aged 18-50 years. The study will show that a new therapeutic human papillomavirus (HPV) vaccine designed to regress a precancerous condition called high-grade squamous intraepithelial…
- Trial name
- NCT01653249
- Testing
- Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Arkansas
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Transplant
Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients
Human papillomavirus (HPV) affects a significant number of transplant patients. In women, human papillomavirus (HPV) causes genital warts, pre-cancerous areas of the cervix, and cervical cancer.
- Trial name
- NCT00677677
- Testing
- Human papillomavirus quadrivalent vaccine
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
HPV Infection, HIV Infection
Human Papillomavirus Infection and Knowledge and Attitudes About HPV Vaccines Among Men Who Have Sex With Men (MSM)
This is a observational study aims to assess anal and genital human papillomavirus (HPV) infection status among men who have sex with men (MSM) in China, and their knowledge and attitude about HPV vaccine.
- Conditions
- HPV Infection, HIV Infection, Syphilis
- Trial name
- NCT01300689
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.